/ /

  • linkedin
  • Increase Font
  • Sharebar

    Honored Lecture: How glaucoma specialty continues to evolve

    Ophthalmologists have more options and can individualize as never before

    Boston—Glaucoma is now in a post-Renaissance period with far superior medications, better lasers, and the potential for individualized treatments for patients, according to Thomas W. Samuelson, MD.

    Glaucoma is a relative new specialty, with the American Glaucoma Society only having been incorporated in 1985. Up until the mid-1990s with the introduction of different medications, the specialty was in its pre-Renaissance period, he said.

    Dr. Samuelson—during his delivery of the Stephen A. Obstbaum, MD, Honored Lecture—recounted that the only anti-glaucoma drugs available were pilocarpine, timolol, and dipivefrin. Surgically, there was trabeculectomy and some ablative procedures.

    “We now have options and we can individualize as never before,” said Dr. Samuelson, Minnesota Eye Consultants, Minneapolis.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results